• Heramed Ltd requests trading halt pending announcement on material customer update and go-to-market strategy in US
• Trading halt to remain in place until Monday, 19 May 2025 or release of announcement
• Halt requested to assist in managing disclosure obligations and maintain orderly market

Heramed Ltd (ASX: HMD) has requested a trading halt on its ordinary shares quoted on the Australian Securities Exchange (ASX). The trading halt has been requested pending an announcement by Heramed regarding a material customer update and its go-to-market strategy in the US due to changes in the business environment. The trading halt will remain in place until the earlier of the commencement of normal trading on Monday, 19 May 2025 or the release of an announcement by the company. Heramed has requested the trading halt to assist in managing its disclosure obligations and to maintain an orderly market in the trading of the company's shares. The company confirms that it is not aware of any reason why the trading halt should not be granted and is not aware of any other information necessary to inform the market about the trading halt.